Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To evaluate gender differences in effectiveness of antihypertensive therapy with losartan in comparison with enalapril therapy. Material and methods. Open-label controlled crossover study in parallel groups was conducted during 3 months. A total of 120 patients aged 20-45 years with arterial hypertension (HT) of 1 and 2 degree were split into 4 groups with 30 patients in each: 1A, 1B – men; 2A, 2B – women. For the first 6 weeks patients of the 1A, 2A groups received enalapril 5-20 mg while patients of 1B, 2B – received losartan 50-100 mg. Then the therapy was crosswise changed. Results. Initial blood pressure (BP) levels did not differ significantly in men and women. In women start therapy with losartan decreased systolic BP (BPs) more effectively than enalapril therapy did (18.2±5.4% vs 15.2±4.3%, р=0.02). In men enalapril and losartan start therapies did not show significant differences in BP reduction (13.8±4.5% vs 14.6±4.6%, р=0.539). Follicule-stimulating hormone (FSH) level in women correlated positively with age (r=0.826; p=0.0001), HT duration (r=0.498; p=0.0001), BPs level (r=0.466; p=0.001), microalbuminuria level (r=0.583; p=0.0001) and negatively – with glomerular filtration rate (r=-0.58; p=0.0001). Conclusion. Losartan is more effective than enalapril as a start therapy in 20-45-year-old women. In women FSH level correlates with age, HT duration, BPs and microalbuminuria levels, glomerular filtration rate.

About the Authors

E. I. Tarlovskaya
Kirov State Medical Academy
Russian Federation
PhD, MD, Professor , Chair of Hospital Therapy

D. A. Suvorova
Kirov State Medical Academy
Russian Federation
MD, Postgraduate Student Hospital Therapy

A. A. Sobolev
Kirov Municipal Hospital №7
Russian Federation
MD, Cief f Doctor


1. National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika 2011; 10 (6) suppl 2: 1-36. Russian (Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика 2011; 10 (6) Приложение 2: 1-36).

2. Shal'nova S.A., Deev A.D., Vikhireva O.V. et al. The prevalence of hypertension in Russia. Awareness, treatment and control. Profilaktika Zabolevaniy i Ukreplenie Zdorov'ya 2001; 2: 3–7. Russian (Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья 2001; 2: 3–7).

3. McCarron P., Smith G.D., Okasha M. et al. Blood pressure in young adulthood and mortality from cardiovascular disease. Lancet 2000; 355:1430–1434.

4. Legato M. Gender and the heart: sex-specific differences in normal anatomy and physiology. Gend Specif Med 2000; 3:15–18.

5. Jochmann N., Stangl K. et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585–1595.

6. Prokhorovich E.A., Tkacheva O.N., Adamenko A.N. Clinical course and treatment of hypertension in women. Trudnyy Patsient 2006;8:13-17. Russian (Про-хорович Е.А., Ткачева О.Н., Адаменко А.Н. Особенности клинического тече-ния и лечения артериальной гипертонии у женщин. Трудный пациент 2006;8:13-17).

7. Hudson M., Rahme E., Behlouli H. et al. Sex differences in the effectiveness of an-giotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure: A population study. Heart Fail 2007; 9:602–609.

8. Cotreau M.M., von Moltke L.L., Greenblatt D.J. The influence of age and sex on the clearance of cytochrome P450 ЗА substrates. Clin Pharmacokinet 2005; 44: 33-60

9. Berg MJ. Drugs, vitamins, and gender. J Gend Specif Med 1999;2(1):18-20.

10. Rathore S.S., Wang Y., Krumboltz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403-1411.

11. Barna O. N. Gender aspects of the coronary artery disease tretment. Novosti Meditsiny i Farmatsii 2009; 274:84-89. Russian (Барна О. Н. Гендерные аспекты лечения ишемической болезни сердца. Новости медицины и фармации 2009; 274:84-89).

12. Ivleva A.Ya. The study of the effectiveness of cardiovascular drugs in women. Kardiologiia 2006; 3:85-89. Russian (Ивлева А.Я. Изучение эффективности сердечно-сосудистых лекарственных средств у женщин. Кардиология 2006; 3:85-89).

13. Tereshchenko S.N., Zhirov I.V. Gender differences in chronic heart failure: myth or reality. Problemy Zhenskogo Zdorov'ya 2007; 1(2):69-74. (Терещенко С.Н., Жиров И.В. Гендерные различия при хронической сердечной недостаточности: миф или реальность. Проблемы женского здоровья 2007; 1(2):69-74).

14. Recommendations to reduce the overall risk of disease and complications in women. Problemy Zhenskogo Zdorov'ya 2009; 3(4):59. Russian (Рекомендации по снижению общего риска развития заболеваний и осложнений у женщин. Проблемы женского здоровья 2009; 3(4):59).

15. Mackay F.J., Pearce G.L. and Mann R.D. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol 1999; 47(1): 111–114.

16. Maychuk E.Yu. Risk factors for cardiovascular disease in women of menopausal period. Meditsinskiy Vestnik 2007; 38-39: 423-424. Russian (Майчук Е.Ю. Факторы риска заболеваний сердечно-сосудистой системы у женщин менопаузального периода. Медицинский вестник 2007; 38-39: 423-424).

17. Smetnik V.P. Arterial hypertension in perimenopausal and postmenopausal women: gender characteristics and the role of estrogen deficiency. Ginekologicheskaya Endokrinologiya 2007;6(9):35-39. Russian (Сметник В.П. Артериальная гипертензия в пери- и постменопаузе: половые особенности и роль дефицита эстрогенов. Гинекологическая эндокринология 2007;6(9):35-39).

18. Williams J. Oestrogen therapy for myocardial ischemia in women. Lancet 1993; 342:128.

19. Judelson D. Coronary heart disease in women: risk faktors and prevention. J Am Med Worn Assoc 1994; 49:186-191.

For citation:

Tarlovskaya E.I., Suvorova D.A., Sobolev A.A. DIFFERENCES IN EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN MEN AND WOMEN: LOSARTAN VERSUS ENALAPRIL. Rational Pharmacotherapy in Cardiology. 2011;7(6):670-676. (In Russ.)

Views: 1999

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)